Almitrine (Vectarion)

A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.

Also Known As:

Networked: 311 relevant articles (32 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dembinski, R: 4 articles (03/2001 - 02/2000)
2.	Rossaint, R: 4 articles (03/2001 - 02/2000)
3.	Payen, Didier: 3 articles (01/2021 - 01/2020)
4.	Kuhlen, R: 3 articles (03/2001 - 02/2000)
5.	Max, M: 3 articles (03/2001 - 02/2000)
6.	Beyls, Christophe: 2 articles (05/2021 - 07/2020)
7.	Dupont, Hervé: 2 articles (05/2021 - 07/2020)
8.	Guilbart, Mathieu: 2 articles (05/2021 - 07/2020)
9.	Haye, Guillaume: 2 articles (05/2021 - 07/2020)
10.	Huette, Pierre: 2 articles (05/2021 - 07/2020)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 05/01/2003 - "Almitrine treatment of patients with severe COPD and moderate hypoxaemia resulted in a small but significant improvement in PaO(2) over 12 months. " 01/01/1986 - "Almitrine bismesylate is a chemoreceptor agonist which has been shown to improve arterial blood gas values in chronic obstructive pulmonary disease (COPD) patients, possibly through better ventilation/perfusion matching. " 01/01/1983 - "1. Almitrine, an agonist of peripheral chemoreceptors, has been shown to be effective in lowering PaCO2 in patients with chronic obstructive lung disease. " 03/01/1987 - "Among five of these patients who were given almitrine bismesylate, an experimental medication thought to alter ventilation-perfusion relationships in patients with chronic obstructive pulmonary disease, one had improved oxygenation. " 03/01/1983 - "Improvement in ventilation-perfusion matching by almitrine in COPD."
2.	Hypoxia (Hypoxemia) 04/01/1983 - "There were greater increases in the response to progressive hypoxia by 78% after 50 mg of almitrine (P less than 0.01) and by 120% after 100 mg (P less than 0.01), which was also significantly greater than the increase after the 50 mg dose (P less than 0.01). " 01/01/1989 - "In the almitrine group (10 subjects), arterial PO2 improved during hypoxia (from 42 +/- 2 to 47 +/- 1 mm Hg, p less than 0.05, mean +/- SEM) and normoxia (from 99 +/- 3 to 104 +/- 2, p less than 0.05). " 01/01/1985 - "This improvement in hypoxia (9%) is negatively related to the initial PaO2 (p less than 0.01) and positively related to almitrine plasma concentrations (p less than 0.05). " 01/01/2023 - "Our study reports a highly variable response to almitrine infusion in ARDS patients with refractory hypoxemia. " 10/01/1990 - "However, in the remaining four fetuses, in which the response to hypoxia was inhibitory, almitrine caused an inhibition of breathing that lasted 184 +/- 28 min. We conclude that the action of almitrine is like that of hypoxia and that, because it acts specifically on the chemoreceptors, it may prove to be a useful tool in the study of possible central chemoreceptor mechanisms."
3.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/01/2021 - "Almitrine infusion improved oxygenation in severe acute respiratory syndrome coronavirus 2-induced acute respiratory distress syndrome without adverse effects. " 01/01/2021 - "Thirty-two patients with acute respiratory distress syndrome received an almitrine infusion trial. " 01/01/2021 - "Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study." 12/01/1999 - "Inhaled NO and almitrine bismesylate in patients with acute respiratory distress syndrome: effect of noradrenalin." 12/01/1999 - "Almitrine and NO in acute respiratory distress syndrome: two pieces of the same puzzle?"
4.	Obstructive Sleep Apnea 12/01/1986 - "These results suggest that almitrine would not be useful in obstructive sleep apnea, yet because almitrine markedly increased VI, f, and VT and decreased TE in unanesthetized sleeping cats the drug may be effective in patients who lack normal central neural respiratory drive, such as the preterm infant." 07/01/1985 - "Previous studies suggest clinical usefulness in the adult with chronic obstructive pulmonary disease, but little data are available to decide whether almitrine would be helpful in diseases involving pharyngeal airway obstruction, such as apnea of prematurity or obstructive sleep apnea. "
5.	Respiratory Insufficiency (Respiratory Failure) 01/01/1990 - "Thus, almitrine bismesylate can be considered useful in the treatment of patients with chronic respiratory insufficiency." 01/01/1986 - "patients with acute respiratory failure entered this preliminary study to evaluate the effects of almitrine bismesylate against placebo. " 10/04/1984 - "Several studies with a 1 year follow-up have shown that almitrine bismesylate represents a breakthrough in the management of respiratory failure consecutive to chronic obstructive respiratory disease. " 01/01/1980 - "[Therapeutic trial of intravenous perfusion of almitrine in acute attacks of respiratory insufficiency]." 01/01/2002 - "Almitrine is used to improve ventilatory drive and ventilation-perfusion matching in respiratory failure. "

Related Drugs and Biologics

1.	Nitric Oxide (Nitrogen Monoxide)
2.	Gases
3.	Almitrine (Vectarion)
4.	Oxygen (Dioxygen)
5.	Epoprostenol (Prostacyclin)
6.	2,4-bis(2-acetoxybenzamido)benzoic acid (AB 50)
7.	Doxapram (Doxapram Hydrochloride)
8.	Cyclooxygenase Inhibitors
9.	raubasine (ajmalicine)
10.	Respiratory System Agents (Respiratory Stimulants)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Artificial Respiration (Mechanical Ventilation)
4.	One-Lung Ventilation
5.	Vagotomy